CPhI report predicts growth in outsourcing for sterile injectables

In the latest installment of CPhI annual reports, Vivek Sharma, CEO of Piramal Pharma Solutions, predicts that there will be a 10% annual growth in the outsourcing of sterile injectables over the next 5 years and that U.S. producers will continue to be favored for that work, followed by CMOs in Western Europe. Among the factors driving that growth, he predicts, will be a preference to outsource high-potency products, demand from companies looking for a backup supplier for a product, growth in emerging markets for generics, and the need for specialized technology from contractors. He pointed specifically to the need for drug delivery systems such as liposomes, PEGlyation, and depot injections as targeted drugs become more a part of the healthcare picture. Release

Suggested Articles

Gilead Sciences will add 140 jobs to its Irish operations as part of an expansion to its Dublin distribution center, the Irish Times reported.

GSK's Shingrix supply has recovered after COVID-19 prompted a slowdown in vaccinations.

Moderna will delegate fill-finish duties for "hundreds of millions" of doses of its COVID-19 vaccine to Spain's Laboratorios Farmacéuticos Rovi.